• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

987
83
62
59
47

COUNTRY

57
19
10
7
5

CATEGORIES

  • 85
  • 124
  • 66
  • 65
  • 37
  • 36
  • 12
  • 12
  • 12
  • 18

PRICE

554
820
1,695
2,700

PUBLISHED

9
159
654
2,700

PRODUCT TYPE

2,593
87
12
7
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE

T-Cell Lymphomas Global Clinical Trials Review, H1, 2014

T-Cell Lymphomas Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, “T-Cell Lymphomas Global Clinical Trials Review, H1, 2014" provides data on the T-Cell Lymphomas clinical...

May 2014
FROM

Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2014

Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2014’, provides an overview...

May 2014
FROM

Uveal Melanoma - Pipeline Review, H1 2014

Uveal Melanoma - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Uveal Melanoma - Pipeline Review, H1 2014’, provides an overview of the Uveal Melanoma’s therapeutic pipeline. This report...

May 2014
FROM

Acute Promyelocytic Leukemia - Pipeline Review, H1 2014

Acute Promyelocytic Leukemia - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Acute Promyelocytic Leukemia - Pipeline Review, H1 2014’, provides an overview of the Acute Promyelocytic...

May 2014
FROM

Mycosis Fungoides - Pipeline Review, H1 2014

Mycosis Fungoides - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Mycosis Fungoides - Pipeline Review, H1 2014’, provides an overview of the Mycosis Fungoides’s therapeutic pipeline. This...

May 2014
FROM

Retinoblastoma - Pipeline Review, H1 2014

Retinoblastoma - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Retinoblastoma - Pipeline Review, H1 2014’, provides an overview of the Retinoblastoma’s therapeutic pipeline. This report...

May 2014
FROM

Germ Cell Tumors - Pipeline Review, H1 2014

Germ Cell Tumors - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Germ Cell Tumors - Pipeline Review, H1 2014’, provides an overview of the Germ Cell Tumors’s therapeutic pipeline. This...

May 2014
FROM

Pancreatic Cancer - Pipeline Review, H1 2014

Pancreatic Cancer - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Pancreatic Cancer - Pipeline Review, H1 2014’, provides an overview of the Pancreatic Cancer’s therapeutic pipeline. This...

May 2014
FROM

Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options

"Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options" provides in-depth analysis of breast cancer market within the Asia-Pacific...

May 2014
FROM

Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies

The current Ovarian cancer therapeutics market is dominated by the use of generics – predominately carboplatin and paclitaxel, which are used in combination for the treatment of platinum-sensitive disease...

May 2014
FROM

EpiCast Report: Non-Hodgkin's Lymphoma - Epidemiology Forecast to 2023

EpiCast Report: Non-Hodgkin's Lymphoma - Epidemiology Forecast to 2023 Summary Non-Hodgkin's lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system In NHL, the body's immune...

May 2014
FROM

Bladder Cancer Treatment Drugs Markets in China

China's demand for bladder cancer treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's...

May 2014
FROM

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023 Summary Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood...

May 2014
FROM

Circulating Tumour Cells (CTCs) and Circulating Nucleic Acids (CNAs) in Research, Clinical & Diagnostics and in Drug R&D: An Integrated Market Study of Developments, Growth Areas and Opportunities

Market findings from this integrated study are based on 'real world' laboratory data, provided by end-users who investigate Circulating Tumour Cells (CTCs) and Circulating Nucleic Acids (CNAs) in the...

May 2014
FROM

Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends and Pipeline Analysis)

“GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline...

May 2014
FROM

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2014

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder...

April 2014
FROM

Ureter Cancer Global Clinical Trials Review, H1, 2014

Ureter Cancer Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, “Ureter Cancer Global Clinical Trials Review, H1, 2014" provides data on the Ureter Cancer clinical trial scenario....

April 2014
FROM

Anaplastic Thyroid Cancer - Pipeline Review, H1 2014

Anaplastic Thyroid Cancer - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Anaplastic Thyroid Cancer - Pipeline Review, H1 2014’, provides an overview of the Anaplastic Thyroid Cancer’s...

April 2014
FROM

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2014

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2014’, provides an overview of...

April 2014
FROM

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2014

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2014’, provides an overview of...

April 2014
FROM
Loading Indicator

Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)